On March 31, 2026, Ambrosia Biosciences, Inc., a privately held drug discovery company, announced a $100 million oversubscribed Series B preferred stock financing. The round was co-led by new investors Blue Owl Healthcare Opportunities, Redmile, and Deep Track Capital. Existing investors BVF Partners and Boulder Ventures also participated, and were joined by additional new investors. Wilson Sonsini Goodrich & Rosati advised Ambrosia Biosciences on the transaction.

The financing is intended to support advancement of Ambrosia Biosciences' oral small molecule GLP-1 candidate and other novel cardiometabolic programs into clinical development.

The Wilson Sonsini team that advised Ambrosia Biosciences on the transaction includes Brent Fassett, Alison Sechrest, and Preston Kramer.

For more information, please see Ambrosia Biosciences' news release. Additional coverage can be found on Fierce Biotech and BioSpace.